Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03574753

Lung-MAP S1400K: c-MET Positive

Recurrent Squamous Cell Lung Carcinoma Clinical Trial

Official title:
A Phase II Study of ABBV-399 in Patients With C-Met Positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP SUB-STUDY)

Clinical Trial Summary

S1400K of Lung-MAP seeks to evaluate the overall response rate with ABBV-399 (Process II) in patients with c-MET positive SCCA. S1400K is a biomarker-driven study for patients with Stage IV or recurrent squamous cell lung cancer, who have c-MET positive squamous cell tumors.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03574753
Study type Interventional
Source Southwest Oncology Group
Contact
Status Completed
Phase Phase 2
Start date March 16, 2018
Completion date July 30, 2021
View Details
See also
  Status Clinical Trial Phase
Withdrawn NCT02536495 - Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer Phase 1/Phase 2
Completed NCT02785939 - Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Phase 2/Phase 3
Completed NCT02965378 - Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Phase 2/Phase 3
Completed NCT03373760 - Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer Phase 2
Completed NCT02785913 - Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Phase 2
Completed NCT03377556 - Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer Phase 2
Terminated NCT02926638 - Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Phase 2/Phase 3
Completed NCT02154490 - Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer
Completed NCT02766335 - Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Phase 2/Phase 3
Terminated NCT00946712 - S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Phase 3
Active, not recruiting NCT02785952 - Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Phase 3